Atherosclerosis progression associated with increased risk of death in asymptomatic individuals

The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September 30 in the Journal of the American College of Cardiology.

This research is also the first to show that advanced imaging can detect atherosclerotic disease of the large vessels long before the appearance of symptoms-;an approach that could be used worldwide to prevent cardiovascular disease and risk of death. Together, the findings emphasize the importance of early detection of atherosclerosis.

The long asymptomatic phase of the disease presents a window of opportunity that has not been exploited in the younger population."

Valentin Fuster, MD, PhD, lead author, President of Mount Sinai Fuster Heart Hospital and General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)

Atherosclerosis is a disease in which lipids, such as cholesterol, and other substances accumulate in plaques on the arterial wall, causing the vessels to harden and narrow, and increasing the risk of severe cardiovascular conditions. Subclinical atherosclerosis is a common condition in which these plaques are present in an artery without causing any symptoms or signs of disease. It can affect people of any age and can lead to serious health conditions including stroke, heart attack, and chronic limb-threatening ischemia.

Despite advances in cardiovascular research, it has remained unclear whether the risk of death from all causes in asymptomatic individuals can be predicted by monitoring the extent and progression of atherosclerosis, especially in the carotid arteries, which supply blood to the brain. 

The goal of the new study, called the BioImage project-;a collaboration between Mount Sinai and the CNIC-;was to determine the independent predictive value of the burden and progression of subclinical atherosclerosis above and beyond what can be predicted using established cardiovascular risk factors.

The study included 5,716 asymptomatic U.S. adults with an average age of 69 years (56.7% women) who were examined from 2008 to 2009. The study participants were examined with two imaging techniques. Atherosclerotic plaques in the carotid arteries were measured with vascular ultrasound, which allows detailed visualization of the interior of blood vessels, and calcification of the coronary arteries was assessed by computed tomography.

A subset of 732 study participants underwent a second vascular ultrasound scan more than eight years after the initial examination. All participants were followed up to determine the rate of death from any cause, the main outcome measure of the study.

Over the 12.4 years of follow-up, 901 (16%) of the participants died. Carotid plaque burden and coronary artery calcification measured at the start of the study were both associated with death from any cause. Moreover, progression of carotid atherosclerosis provided further prognostic information and was independently associated with all-cause mortality. 

"Vascular ultrasound is a non-invasive and affordable test, and the valuable prognostic information it provides can be used to improve risk stratification and to target lifestyle recommendations for the control of cardiovascular risk factors," explains Borja Ibáñez, PhD, Scientific Director of the CNIC.

The study concluded that detecting subclinical atherosclerosis early and monitoring its progression can improve the prediction and prevention of death from any cause, offering a valuable tool for clinical practice.

Source:
Journal reference:

Fuster, V., et al. (2024) Influence of subclinical atherosclerosis burden and progression on mortality Short title: Subclinical atherosclerosis and mortality. Journal of the American College of Cardiologydoi.org/10.1016/j.jacc.2024.06.045.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough metabolomic aging score that predicts mortality better than traditional methods